Results 151 to 160 of about 1,266 (177)
Implementation of a Metered-Dose Inhaler to Dry-Powder Inhaler National Formulary Transition.
JAMA Netw OpenRabin AS +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Olodaterol: First Global Approval
Drugs, 2013Olodaterol (Striverdi(®) Respimat(®)) is a novel, long-acting, β2-adrenergic receptor agonist developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD). The drug is delivered via the Respimat(®) Soft Mist™ inhaler. Olodaterol received its first global approval for the once-daily maintenance treatment of COPD in
Andrew, Gibb, Lily P H, Yang
openaire +2 more sources
Olodaterol and vilanterol detection in sport drug testing
Drug Testing and Analysis, 2015The possibility of the detection of olodaterol and vilanterol, two novel β2‐agonists, in human urine for the purpose of sport drug testing was investigated. Compounds of interest were analyzed by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) employing methods commonly used in the World Anti‐Doping Agency (WADA) accredited laboratories.
Zdenek Chundela, Joachim Große
openaire +2 more sources
▼Olodaterol—another LABA for COPD
Drug and Therapeutics Bulletin, 2015▼Olodaterol solution for inhalation (Striverdi Respimat—Boehringer Ingelheim) is a long-acting beta2 agonist (LABA) licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). This is the third LABA to be licensed in the UK for once-daily use for patients with COPD. DTB has previously reviewed the
openaire +2 more sources
Tiotropium/Olodaterol: A Review in COPD
Drugs, 2015Tiotropium/olodaterol (Stiolto™ Respimat®, Spiolto™ Respimat®) is a fixed-dose combination of the long-acting antimuscarinic agent tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenoreceptor agonist olodaterol delivered via the Respimat® Soft Mist™ inhaler.
openaire +2 more sources
Effect of olodaterol on the relaxation of small airways
European Respiratory Journal, 2011Olodaterol (Ol) is a novel, selective, β 2 -agonist which offers bronchoprotection in mild asthmatics with duration of action of at least 24h. Small airways are the major site of obstruction in patients with COPD.
Stephanie M. Brown +2 more
openaire +1 more source
Olodaterol attenuates bleomycin induced lung fibrosis in mice
5.1 Airway Pharmacology and Treatment, 2016Background: The long-acting β 2 -agonist (LABA) olodaterol was shown to have anti-fibrotic activity in primary human lung fibroblasts (Herrmann et al, Eur Respir J. 2014;44:Suppl.58) however, its anti-fibrotic in vivo efficacy has not yet been demonstrated. Aim: To test the effect of olodaterol in a mouse model of bleomycin induced lung fibrosis.
Franziska Herrmann +3 more
openaire +1 more source
Olodaterol: Once-daily inhalation spray for COPD
Pharmacy Today, 2014FDA has approved olodaterol (Striverdi Respimat—Boehringer Ingelheim), a once-daily inhalation spray to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The long-acting beta-adrenergic agonist (LABA), delivered via a propellant-free inhaler, helps the muscles around ...
openaire +1 more source
Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol
The Journal of Pharmacology and Experimental Therapeutics, 2011β(2)-Adrenoceptor (β(2)-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease. Although these agents first were used many years ago, progress in drug development has resulted in better tolerated, long-acting β(2)-AR agonists (LABAs),
Paola, Casarosa +8 more
openaire +2 more sources